Co-Authors
This is a "connection" page, showing publications co-authored by Giulia Radi and Anna Campanati.
Connection Strength
1.218
-
Active implications for dermatologists in 'SARS-CoV-2 ERA': Personal experience and review of literature. J Eur Acad Dermatol Venereol. 2020 Aug; 34(8):1626-1632.
Score: 0.224
-
How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic. Dermatol Ther. 2020 Jul; 33(4):e13740.
Score: 0.222
-
Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020 05; 34(5):e213-e214.
Score: 0.220
-
Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021 Jul; 35(7):e428-e430.
Score: 0.059
-
Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan; 34(1):e14547.
Score: 0.057
-
Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVID-19 era. Int J Dermatol. 2020 Nov; 59(11):1411-1413.
Score: 0.057
-
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. Dermatol Ther. 2020 Nov; 33(6):e14256.
Score: 0.056
-
Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center. Australas J Dermatol. 2021 02; 62(1):e158-e159.
Score: 0.056
-
Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association. J Med Virol. 2021 01; 93(1):5-7.
Score: 0.056
-
Global coronavirus pandemic (SARS-CoV-2): Past, present, and future of pediatric dermatology. Dermatol Ther. 2020 09; 33(5):e13767.
Score: 0.056
-
Skin involvement in SARS-CoV-2 infection: Case series. J Med Virol. 2020 11; 92(11):2332-2334.
Score: 0.055
-
Familial lupus panniculitis: two cases, same diagnosis, what evolution? G Ital Dermatol Venereol. 2020 Dec; 155(6):791-793.
Score: 0.050
-
Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience. G Ital Dermatol Venereol. 2020 Dec; 155(6):739-743.
Score: 0.050